NCT00446654 - Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions

Age Related Macular Degeneration

Interventions

DRUG

CGC-11047

16.5 mg (3.3%) subconjunctival injection

Trial Locations (8)

21287

Wilmer Eye Institute, Baltimore

Unknown

Dr. Quiroz-Mercado, Mexico City

"Federal State Establishment Intersectoral Research and Technology Complex Eye Microsurgery named by Academic SN Fyodorov of Federal Agency for Healthcare and Social Development", Cheboksary

"Federal State Establishment Intersectoral Research and Technology Complex Eye Microsurgery named by Academic SN Fyodorov of Federal Agency for Healthcare and Social Development", Moscow

"Closed Joint Stock Company Inter YuNA", Rostov-on-Don

"Federal State Establishment Intersectoral Research and Technology Complex Eye Microsurgery named by Academic SN Fyodorov of Federal Agency for Healthcare and Social Development", Saint Petersburg

"Saint Petersburg State Healthcare Establishment City Consultative Diagnostic Centre #1", Saint Petersburg

"State Educational Establishment of Higher Professional Education Military Medical Academy named by SM Kirov", Saint Petersburg